Parents and grandparents rarely disagree about how cute their (grand)children are, but when it comes to setting up safe sleep environments for babies, the two generations don’t always concur, according to a new study conducted by Ipsos Public Affairs on behalf of HALO Innovations in time for National Baby Safety Month. The survey found that the majority of parents and grandparents agree that Sudden Infant Death Syndrome (SIDS) is their top concern in raising their children. However, grandparents are more likely than parents to place babies on their sides or stomachs to sleep, and more likely to place potentially dangerous objects in babies’ cribs, increasing their risk for SIDS and accidental suffocation.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/halosleepsacks/46013/
http://www.babysleepsolution.com Useful tips on how parents can reduce the risk of SIDS or Cot Death. Baby sleep safety tips.
Baby sleep safety
Baby sleep problems
Baby sleep information
http://igetitapps.com/ i Get It offers some of the best educational apps for iPad, iPhone and iPod Touch, autism apps, and iPad apps for special needs kids. i Get It applications are designed to support language skill development and facilitate cognitive growth through building language skills. Typically developing young children and individuals with developmental delays, such as PDD-NOS, autism, down syndrome or TBI will benefit from these interactive applications. Autism apps have been recently featured on TV shows as a great way of communication for people whose condition prevents them from speaking. i Get It apps have been featured on AutismSpeaks.org, Snapps4kids.com, A4cwsn and many others. Please go to http://igetitapps.com/ to see all our apps.
Almirall, S.A. (ALM:MC) and Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that the European Commission has granted marketing authorization to Constella® (linaclotide 290mcg) for the symptomatic treatment of moderate to severe Irritable Bowel Syndrome with Constipation (IBS-C) in adults . This approval follows the positive recommendation received from the European Committee for Medicinal Products for Human Use (CHMP) in September.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58658-almirall
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
